<DOC>
	<DOC>NCT02392494</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and pharmacokinetics of MK-1075, and to determine the ability of MK-1075 to reduce HCV viral load, following administration of a single dose in HCV-infected participants.</brief_summary>
	<brief_title>Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Male or female of nonchild bearing potential In good health other than HCV genotype (GT) 1 infection Is mentally incapacitated or legally institutionalized Has a history of clinically significant and not stably controlled endocrine, gastrointestinal, cardiovascular, hematological, hepatic (excepting HCV infection), immunological, renal, respiratory, genitourinary or major neurological (including stroke and chronic seizures) abnormalities or diseases Has a history of cancer Is positive for hepatitis B surface antigen (HBsAg) or human immunodeficiency virus (HIV) Has participated in another investigational trial within 4 weeks (or 5 halflives) prior to Screening Consumes &gt;2 alcoholic beverages a day or uses illegal drugs Has evidence or history of chronic hepatitis not caused by HCV including but not limited to nonHCV viral hepatitis, nonalcoholic steatohepatitis (NASH), druginduced hepatitis, or autoimmune hepatitis Has clinical or laboratory evidence of advanced or decompensated liver disease, evidence of bridging fibrosis or higher grade fibrosis (Metavir score â‰¥3) from prior liver biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>